Access Statistics for László Gulácsi

Author contact details at EconPapers.

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective 0 0 0 1 0 1 7 39
Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries 0 0 0 1 2 2 5 32
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries 0 0 0 8 0 0 6 48
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis 0 0 0 3 2 2 7 46
Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries 0 1 1 6 1 2 4 88
Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres 0 0 0 5 2 3 10 57
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison 0 0 0 2 0 1 3 36
Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics 0 0 0 0 1 1 3 30
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary 0 0 0 4 1 1 5 61
Future challenges for health economics and health technology assessment of biological drugs 0 0 0 24 0 0 3 90
HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain 0 0 0 7 1 1 1 38
Health economics and health technology assessment in Central and Eastern Europe: a dose of reality 0 0 0 12 2 3 5 51
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria 0 0 0 9 1 1 3 62
Preferences of Hungarian consumers for quality, access and price attributes of health care services — result of a discrete choice experiment 0 0 0 14 1 1 8 122
Quality management and patient safety: Survey results from 102 Hungarian hospitals 0 0 0 39 1 1 4 216
Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists 0 0 0 3 0 0 5 37
The disease burden of colorectal cancer in Hungary 0 0 0 23 0 0 1 133
The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study 0 0 0 5 2 4 8 52
The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience 0 0 0 18 0 0 3 58
Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries 0 0 0 0 4 4 6 30
User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders 0 1 2 10 1 3 10 57
Verseny az egészségügyben. Egyesült államokbeli és nyugat-európai példák 0 0 0 7 3 3 9 48
Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics 0 0 0 5 3 4 5 54
Total Journal Articles 0 2 3 206 28 38 121 1,485

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-05-06